Agoracom Blog Home

Posts Tagged ‘Vaccine’

Mountain Valley MD $MVMD $MVMDF Holdings Inc. Proceeding with Application to List on the TSX Venture Exchange $CTLT $MRNA $NVAX

Posted by AGORACOM-Eric at 8:47 AM on Tuesday, April 20th, 2021

Mountain Valley MD Holdings Inc. (the “Company” or “MVMD“) (CSE: MVMD) (FRA:20MP) (OTCQB: MVMDF) is pleased to announce that it is proceeding with the application for the listing of its shares for trading on the TSX Venture Exchange (“TSXV”).  The Company’s board of directors has approved the move and the Company intends to submit an application to the TSXV this week.

“We believe that pursuing a listing on the TSX-V is a great step for Mountain Valley MD Holdings Inc. and will provide increased liquidity and trading capabilities in MVMD’s common shares for both institutional and retail investors,” stated Dennis Hancock, President and CEO of Mountain Valley MD.  “This is a significant part of our efforts to broaden our appeal to a larger shareholder base and continue to raise the Company’s profile among the North American investment community.”

Completion of the listing on the TSXV is subject to the satisfaction of listing requirements and the approval of the TSXV.  In the meantime, MVMD’s shares will continue to trade on the Canadian Securities Exchange under the ticker symbol “MVMD”.  Further updates will be provided as they become available.

ABOUT MOUNTAIN VALLEY MD HOLDINGS INC
Mountain Valley MD is building a world-class biotech and life sciences company organization centred around the implementation of its patented Quicksome™ oral drug formulation and delivery technologies and its Quicksol™ solubilization technology for macrocyclic lactones, to innovate industry leading products that are sought out globally.

MVMD’s proposition for delivering Quicksome™ formulations that have rapid onset, high bioavailability, low variability and precision dosing is core to the Company’s success across key health and wellness categories. Consistent with its vision towards “Helping People Live Their Best Life”, MVMD applies its Quicksome™ and Quicksol™ technologies to its ground-breaking work for advanced delivery of vaccines and pharmaceutical drugs as well as the development of products for pain management, weight loss, energy, focus, sleep, anxiety, and more.

The Company’s patented Quicksome™ desiccation technology utilizes advanced liposomes and other stabilizing molecules to encapsulate and formulate active ingredients into highly efficient product formats that are consumed orally.  The result is a new generation of product formulations that are capable of delivering vaccines, drugs and nutraceuticals into the body faster, with greater impact, efficiency and accuracy. 

Read More: https://agoracom.com/ir/MountainValleyMD/forums/discussion/topics/759352-mountain-valley-md-holdings-inc-proceeding-with-application-to-list-on-the-tsx-venture-exchange/messages/2312668#message

Mountain Valley MD $MVMD $MVMDF Commencing Trials in Bangladesh, Striking Pharmaceutical Production Agreements $CTLT $MRNA $NVAX

Posted by AGORACOM-Eric at 10:31 AM on Tuesday, March 16th, 2021

Mountain Valley MD Holdings Inc. (the “Company” or “MVMD“) (CSE: MVMD) (FRA: 20MP) (OTCQB: MVMDF) is pleased to announce it is commencing husbandry animal trials under the supervision of The People’s Republic of Bangladesh’s Ministry of Fisheries & Livestock for the Company’s injectable solubilized Ivermectin technology, Ivectosol™ 1%.

“We are very excited to be welcoming Mountain Valley MD to The People’s Republic of Bangladesh and are proud that they have selected our country for important research projects and as a key production hub for its solubilized Ivectosol™ 1% product,” stated Bangladesh’s Foreign Minister H.E. Dr. A. K. Abdul Momen, M.P.

MVMD is working with its local partner R&G Group inside Bangladesh to quickly advance its research and development, and manufacturing capabilities inside the country.

MVMD’s Ivectosol™ 1%, a fully solubilized form of the anti-parasitic drug Ivermectin, will be tested in cattle, goat and poultry under the supervision of the Bangladesh Government’s approved and authorized laboratories and research institutes.  The tests will be conducted by way of intra-muscular needleless injection of Ivectosol™ 1% in an effort to demonstrate superior pharmacokinetics in terms of CMAX (peak serum concentration that a drug achieves) and AUC (area under the curve) with advanced drug withdrawal time control, versus current commercially available forms.

The trials are scheduled to commence in early April, 2021 and are anticipated to take 30 days.  The trial results are scheduled to be reviewed and approved by the Ministry of Fisheries & Livestock and Ministry of Health and will enable the Company to advance against immediate commercialization opportunities.  The Company is finalizing production supply agreements with key Bangladesh pharmaceutical partners to produce its Ivectosol™ 1% for use and distribution throughout Bangladesh and as a production hub for broader global distribution.  The production scheduling and pricing are currently being finalized under non-disclosure agreement (“NDA”), including securing the sufficient Ivermectin Active Pharmaceutical Ingredient (“API”) quantity for anticipated global demand.

“We’ve been extremely impressed by the speed and pace with which the Government of the People’s Republic of Bangladesh continues to provide our teams with incredible support for the testing and preparedness of an accelerated commercialization pathway for Ivectosol™ 1%,” stated Dennis Hancock, President and CEO of Mountain Valley MD.  “Our pharmaceutical partners are both FDA and EU compliant and support our broader objectives to scale for global production.  Securing top quality manufacturing within a competitive cost structure is critical to align with one of the core tenets of MVMD’s mission to ensure accessibility to our technology for even the most disadvantaged nations.”

Read More: https://agoracom.com/ir/MountainValleyMD/forums/discussion/topics/757425-mountain-valley-md-commencing-trials-in-bangladesh-striking-pharmaceutical-production-agreements/messages/2308370#message

Mountain Valley MD $MVMD $MVMDF Achieves Solubilization of Selamectin, Files Trademark For Selactosol™ $CTLT $MRNA $NVAX

Posted by AGORACOM-Eric at 10:15 AM on Wednesday, March 10th, 2021
  • Mountain Valley MD Files Trademark For Selactosol™

Mountain Valley MD Holdings Inc. (the “Company” or “MVMD“) (CSE: MVMD) (FRA: 20MP) (OTCQB: MVMDF) is pleased to announce it has achieved a water solubilized selamectin product using its patent-pending Quicksol™ technology.  To date, selamectin was considered a virtually water insoluble molecule with tremendous potential in treating parasitic infestations in husbandry and companion animals, as well as mycobacterium-based infections including Buruli Ulcer, Leprosy and Tuberculosis.

MVMD scientists successfully solubilized selamectin at 15mg/ml into a water solution without any organic solvents, which it believes is a critical achievement to allow formulation into topical application creams, oral rapid dissolve sublingual tablets, and injectable applications.

“We continue to accelerate our focus and efforts on solving the most significant human and husbandry animal health problems facing our global population,” stated Dennis Hancock, President and CEO of Mountain Valley MD.  “We are very optimistic that this breakthrough on selamectin will help MVMD pursue near term licensing and commercialization opportunities consistent with our business plan.”

The Company has filed for trademark protection under the brand name Selactosol™ to support its continuing work within the Quicksol™ line of water solubilized macro-cyclic lactones.  The Company has focused its initial efforts on already approved macro-cyclic lactones given its belief that they will yield the broadest commercialization opportunities in the shortest period of time.

Having successfully applied the Quicksol™ solubilization technique to the selamectin drug, MVMD will now proceed to formulate Selactosol™ 1.5% for preclinical evaluation trials of mycobacterium-based infections such as Buruli Ulcer, Leprosy and Tuberculosis.

“We believe this discovery to be a breakthrough that will enable the efficacy needed to treat respiratory infections such as tuberculosis by enabling the drug deposition into the airways and lungs through injections, aerosol formulations and pulmonary delivery,” stated Mike Farber, Director of Life Sciences at Mountain Valley MD.  “We are anxiously looking forward to proving the efficacy of this breakthrough in multi-drug and extended drug resistant strains of tuberculosis.”

Read More: https://agoracom.com/ir/MountainValleyMD/forums/discussion/topics/756963-mountain-valley-md-achieves-solubilization-of-selamectin-files-trademark-for-selactosol/messages/2307352#message

VIDEO – Mountain Valley MD $MVMD.ca Patent Filing Creates New Global Delivery And Patient Delivery Model That Can Eradicate Polio From The World …. Then Other Viruses $CTLT $MRNA $NVAX

Posted by AGORACOM-JC at 6:55 PM on Wednesday, January 20th, 2021
http://blog.agoracom.com/wp-content/uploads/2021/01/Mountain-Valley-300x300-1.jpg

Let us start off by saying this interview may be the best one we’ve done in the last 10 years.  Here is why.

When Mountain Valley MD issued this press release today, you wouldn’t be alone if you declared “I really don’t know what that means”.  The fact of the matter is that MVMD is a double-edged sword that puts it in a position to quite potentially change the way the world delivers drugs and vaccines via physical transport and into the body of patients who need them most.  The flip-side of creating something so cutting edge is that it makes it very difficult to understand for anybody without a Life Sciences PhD.

Fortunately, this is where AGORACOM comes in to bridge the worlds between MVMD and the investment community.  To do that, the first thing you have to understand is the following:

MVMD Takes Existing Vaccines and Drugs – And Delivers Them Better.  Both Into The Body and By Transportation To The World. Way Better.

For the purposes of introducing you to MVMD, we’ll use vaccines as an example given the state of the world since COVID-19 arrived.  Specifically, we’ve all heard more about vaccines in 12 months than we have in the last 12 years.  One thing we all know about vaccines is that vaccination is the safest way to protect people against infectious diseases.

BUT 

One thing we don’t know or understand about vaccinations is that they are only as good as:

1.  The global physical delivery system that actually gets them from the manufacturer to the hands of nurse who injects the vaccine;

2.  The delivery system into your body (i.e. injection)

If either parts of these delivery systems are weak, or even fail, a vaccine loses some or even all of its potency – and that’s not good.

This is where MVMD comes in.  They don’t make vaccines, drugs or pharmaceuticals.

What they do is make their delivery better.  Their physical delivery until their ultimate delivery into your body – and that is very good.

By doing so, they help save lives and they help manufacturers be more profitable – and that is very good for humanity and shareholders.

CAN MVMD CREATE A WORLD WITHOUT POLIO … AND THEN OTHER VIRUSES? THEY JUST MIGHT

With the information above in mind, you can now start to get a sense of the power of this quote from MVMD CEO, Dennis Hancock:

“Using a fraction of the Inactivated Polio Vaccine, applying advanced Quicksome™ thin film inside a vial that can be distributed completely outside of the cold chain, and administering through needleless applications is the formula to help us achieve our vision of a world without Polio“. 

If you want to find out what is possible, watch this powerful, eye-opening and sometimes emotional interview with CEO Dennis Hancock and Director of Life Sciences Mike Farber.

The COVID-19 Treatment Guidelines Panel’s Statement on the Use of Ivermectin for the Treatment of COVID-19 SPONSOR: Mountain Valley MD $MVMD.ca $CTLT $MRNA $NVAX

Posted by AGORACOM-Eric at 12:53 PM on Friday, January 15th, 2021

SPONSOR: Mountain Valley MD has confirmed the ability to make the drug ivermectin water-soluble without the use of organic solvents, greatly increasing the potential applications for treatment. MVMD has Improved ivermectin’s water solubility by nearly 5000 times more than current solubility  Click Here for More Info

  • The NIH has upgraded their recommendation and now consider IVERMECTIN an option for use! The national Institute of Health

Recommendation

  • The COVID-19 Treatment Guidelines Panel (the Panel) has determined that currently there are insufficient data to recommend either for or against the use of ivermectin for the treatment of COVID-19. Results from adequately powered, well-designed, and well-conducted clinical trials are needed to provide more specific, evidence-based guidance on the role of ivermectin for the treatment of COVID-19.

Rationale

Ivermectin is an antiparasitic drug that is approved by the Food and Drug Administration (FDA) for the treatment of onchocerciasis and strongyloidiasis. Ivermectin is not FDA-approved for the treatment of any viral infection. In general, the drug is well tolerated. It is currently being evaluated as a potential treatment for COVID-19.

Antiviral and Anti-Inflammatory Effects of Ivermectin

Reports from in vitro studies suggest that ivermectin acts by inhibiting the host importin alfa/beta-1 nuclear transport proteins, which are part of a key intracellular transport process that viruses hijack to enhance infection by suppressing the host antiviral response.1,2 In addition, ivermectin docking in vitro may interfere with the attachment of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein to the human cell membrane.3

Ivermectin has been shown to inhibit the replication of SARS-CoV-2 in cell culture. However, pharmacokinetic and pharmacodynamic studies suggest that ivermectin doses up to 100-fold higher than those approved for use in humans would be required to achieve the plasma concentrations necessary to duplicate the drug’s antiviral efficacy in vitro.4,5 Even though ivermectin appears to accumulate in lung tissue, with the doses used in most clinical trials, predicted systemic plasma and lung tissue concentrations are much lower than 2 µM, the half-maximal inhibitory concentration (IC50) against SARS-CoV-2 in vitro.6,7

Ivermectin demonstrates potential anti-inflammatory properties in some in vitro studies,8,9 properties which have been postulated to be beneficial in the treatment of COVID-19.10

Clinical Data

Since the last revision of the Ivermectin section of the Guidelines, the results of several randomized trials and retrospective cohort studies of ivermectin use in patients with COVID-19 have been published in peer-reviewed journals or made available as preliminary, non-peer-reviewed reports. Some clinical studies showed no benefits or worsening of disease after ivermectin use,11-14 whereas others reported shorter time to resolution of disease manifestations attributed to COVID-19,15-18 greater reduction in inflammatory markers,16,17 shorter time to viral clearance,11,16 or lower mortality rates in patients who received ivermectin than in patients who received comparator drugs or placebo.11,16,18

However, most of the studies reported to date had incomplete information and significant methodological limitations, which make it difficult to exclude common causes of bias. The missing information and limitations include the following:

  • The sample size of most of the trials was small.
  • Various doses and schedules of ivermectin were used.
  • Some of the randomized controlled trials were open-label studies in which neither the participants nor the investigators were blinded to the treatment arms.
  • In addition to ivermectin or the comparator drug, patients also received various concomitant medications (e.g., doxycycline, hydroxychloroquine, azithromycin, zinc, corticosteroids), confounding assessment of the true efficacy or safety of ivermectin.
  • The severity of COVID-19 in the study participants was not always well described.
  • The study outcome measures were not always clearly defined.

Because of these limitations, the Panel cannot draw definitive conclusions about the clinical efficacy or safety of ivermectin for the treatment of COVID-19. Results from adequately powered, well-designed, and well-conducted clinical trials are needed to provide more specific, evidence-based guidance on the role of ivermectin for the treatment of COVID-19.

SOURCE: https://www.covid19treatmentguidelines.nih.gov/statement-on-ivermectin/